ReviewNature reviews. Cancer2013
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.
Review in Nature reviews. Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 339 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
339 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Correlation between ALK+ non-small cell lung cancer targeted therapy and thrombosis: a systematic review and network meta-analysis.BMJ open · 2024Pooled it
- Hypoxia-inducible factor 1alpha and vascular endothelial growth factor in Glioblastoma Multiforme: a systematic review going beyond pathologic implications.Oncology research · 2024Pooled it
- The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer.Journal of experimental & clinical cancer research : CR · 2022Pooled it
- Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Guideline
- Association of immune relevant single nucleotide polymorphisms with ALK-positive anaplastic large cell lymphoma presentation and outcome: results of the immuno ALCL study.Journal of translational medicine · 2025Trial
- ALK ATI in solid tumours: biological evidence, diagnostic challenges, and clinical relevance. a narrative review.Molecular biology reports · 2026Review
- Oncohistone inhibition reshapes tumor-microenvironment communication in Diffuse Midline Glioma (DMG).bioRxiv : the preprint server for biology · 2026Article
- Renal cell carcinoma with a novel RAB1A::ALK fusion: expanding the molecular spectrum of ALK-rearranged RCC.Virchows Archiv : an international journal of pathology · 2026Article
- Three decades of anaplastic lymphoma kinase: from physiological roles to cancer and immune evasion.Cancer metastasis reviews · 2026Review
- ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.Cancer chemotherapy and pharmacology · 2026Review
- Pancreatic ductal adenocarcinoma with ITSN1-ALK fusion: sustained response to alectinib with 19-month progression-free survival.The oncologist · 2026Article
- ALK Inhibitor Response in NovelJTO clinical and research reports · 2026Article
- A Giant Thoracic ALK-Rearranged Mesenchymal Neoplasm in a Child.Cancer reports (Hoboken, N.J.) · 2026Article
- Erastin-induced ferroptosis enhances natural killer cell anti-tumor activity and offers therapeutic potential in neuroblastoma.Frontiers in immunology · 2026Article
- Recent developments in eosinophilic renal neoplasms: what's new, true and important?Histopathology · 2026Review
- Primary pulmonary mesenchymal malignancy associated with paraneoplastic pemphigus: a case report.Frontiers in medicine · 2026Article
- OncogenicLung cancer management · 2025Article
- Crizotinib- or Ceritinib-Conjugated Platinum(IV) Prodrugs As Potent Multiaction Agents Inducing Antiproliferative Effects in 2D and 3D Cancer Cell Models.Journal of medicinal chemistry · 2025Article
- ALK rearranged malignant mesenchymal neoplasms of thorax: therapeutically targetable 'ALKomas' beyond the spectrum of non-small cell lung carcinomas and thoracic inflammatory myofibroblastic tumors.Virchows Archiv : an international journal of pathology · 2025Article
- Lung adenocarcinoma withTranslational lung cancer research · 2025Article
279 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC). The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK. In this Review, we discuss our current understanding of ALK function in human cancer and the implications for tumour treatment.
Indexed as
Identifiers
24060861What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.